Cardiovascular disease continues to be the major cause of morbidity and mortality in the United States, and is an emerging epidemic world-wide. In particular atherosclerosis is a life-threatening disease strongly associated with risk factors such as hypercholesterolemia, hypertension and diabetes. Importantly, in the face of these potent systemic drivers of cardiovascular risk, certain regions of the arterial vasculature nonetheless remain relatively resistant to the development of atherosclerotic lesions. Several lines of evidence suggest that hemodynamically distinct environments in these arterial geometries exert a protective influence on the vascular endothelium, thus inhibiting early lesion development. However, despite recent progress in our understanding of the transcriptional activators responsible for this ?vasoprotection?, this progress has not yet been translated into therapeutic strategies for cardiovascular disease due to the lack of mechanistic understanding of the proximal signaling pathways activated by vasoprotective flow. In this project, previously unrecognized actions of doxorubicin in vascular endothelial cells, recently uncovered in our laboratory, will provide the basis for establishing a novel conceptual and experimental framework seeking to identify novel mechano-activated signaling pathways in the vascular endothelium. To this end, we will perform a loss-of-function screen in human endothelial cells to gain insights into the mechanism of action of doxorubicin-mediated loss of flow-dependent endothelial vasoprotection. Ultimately, the identification of the molecular target(s) of doxorubicin in endothelial cells should contribute to our understanding of how these cells sense, integrate and respond to vasoprotective flow, and could help in the development on new therapeutic interventions against endothelial cell dysfunction.

Public Health Relevance

Heart attacks and strokes continue to be the major cause of death in the U.S. Therefore, there is a critical need for additional drugs and therapies for the prevention and treatment of cardiovascular disease. This project seeks to mechanistically define how certain regions of blood vessels are protected from the development of disease because they are exposed to a defined type of blood flow.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL152367-01
Application #
9969959
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Gao, Yunling
Project Start
2020-05-01
Project End
2022-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115